4.6 Article

Functional Characterization of a Newly Identified Group B Streptococcus Pullulanase Eliciting Antibodies Able to Prevent Alpha-Glucans Degradation

Journal

PLOS ONE
Volume 3, Issue 11, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0003787

Keywords

-

Funding

  1. Novartis Vaccines & Diagnostic

Ask authors/readers for more resources

Streptococcal pullulanases have been recently proposed as key components of the metabolic machinery involved in bacterial adaptation to host niches. By sequence analysis of the Group B Streptococcus (GBS) genome we found a novel putative surface exposed protein with pullulanase activity. We named such a protein SAP. The sap gene is highly conserved among GBS strains and homologous genes, such as PulA and SpuA, have been described in other pathogenic streptococci. The SAP protein contains two N-terminal carbohydrate-binding motifs, followed by a catalytic domain and a C-terminal LPXTG cell wall-anchoring domain. In vitro analysis revealed that the recombinant form of SAP is able to degrade alpha-glucan polysaccharides, such as pullulan, glycogen and starch. Moreover, NMR analysis showed that SAP acts as a type I pullulanase. Studies performed on whole bacteria indicated that the presence of alpha-glucan polysaccharides in culture medium up-regulated the expression of SAP on bacterial surface as confirmed by FACS analysis and confocal imaging. Deletion of the sap gene resulted in a reduced capacity of bacteria to grow in medium containing pullulan or glycogen, but not glucose or maltose, confirming the pivotal role of SAP in GBS metabolism of alpha-glucans. As reported for other streptococcal pullulanases, we found specific anti-SAP antibodies in human sera from healthy volunteers. Investigation of the functional role of anti-SAP antibodies revealed that incubation of GBS in the presence of sera from animals immunized with SAP reduced the capacity of the bacterium to degrade pullulan. Of interest, anti-SAP sera, although to a lower extent, also inhibited Group A Streptococcus pullulanase activity. These data open new perspectives on the possibility to use SAP as a potential vaccine component inducing functional cross-reacting antibodies interfering with streptococcal infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

FAT1: a potential target for monoclonal antibody therapy in colon cancer

Piero Pileri, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Elisa De Camilli, Chaojun Song, Luisa Ganfini, Aurelien Lacombe, Ilaria Naldi, Paolo Sarmientos, Caterina Cinti, Boquan Jin, Guido Grandi, Giuseppe Viale, Luigi Terracciano, Renata Grifantini

BRITISH JOURNAL OF CANCER (2016)

Article Immunology

Auto-Assembling Detoxified Staphylococcus aureus Alpha-Hemolysin Mimicking the Wild-Type Cytolytic Toxin

Luigi Fiaschi, Benedetta Di Palo, Maria Scarselli, Clarissa Pozzi, Kelly Tomaszewski, Bruno Galletti, Vincenzo Nardi-Dei, Letizia Arcidiacono, Ravi P. N. Mishra, Elena Mori, Michele Pallaoro, Fabiana Falugi, Antonina Torre, Maria Rita Fontana, Marco Soriani, Juliane Bubeck Wardenburg, Guido Grandi, Rino Rappuoli, Ilaria Ferlenghi, Fabio Bagnoli

CLINICAL AND VACCINE IMMUNOLOGY (2016)

Article Biotechnology & Applied Microbiology

Large scale validation of an efficient CRISPR/Cas-based multi gene editing protocol in Escherichia coli

Francesca Zerbini, Ilaria Zanella, Davide Fraccascia, Enrico Koenig, Carmela Irene, Luca F. Frattini, Michele Tomasi, Laura Fantappie, Luisa Ganfini, Elena Caproni, Matteo Parri, Alberto Grandi, Guido Grandi

MICROBIAL CELL FACTORIES (2017)

Article Biochemical Research Methods

Some Gram-negative Lipoproteins Keep Their Surface Topology When Transplanted from One Species to Another and Deliver Foreign Polypeptides to the Bacterial Surface

Laura Fantappie, Carmela Irene, Micaela De Santis, Alessandro Armini, Assunta Gagliardi, Michele Tomasi, Matteo Parri, Valeria Cafardi, Serena Bonomi, Luisa Ganfini, Francesca Zerbini, Ilaria Zanella, Chiara Carnemolla, Luca Bini, Alberto Grandi, Guido Grandi

MOLECULAR & CELLULAR PROTEOMICS (2017)

Article Oncology

TCTN2: a novel tumor marker with oncogenic properties

David Cano-Rodriguez, Susanna Campagnoli, Alberto Grandi, Matteo Parri, Elisa De Camilli, Chaojun Song, Boquan Jin, Aurelien Lacombe, Andrea Pierleoni, Mauro Bombaci, Chiara Cordiglieri, Marcel H. J. Ruiters, Giuseppe Viale, Luigi Terracciano, Paolo Sarmientos, Sergio Abrignani, Guido Grandi, Piero Pileri, Marianne G. Rots, Renata Grifantini

ONCOTARGET (2017)

Article Oncology

Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles

Alberto Grandi, Michele Tomasi, Ilaria Zanella, Luisa Ganfini, Elena Caproni, Laura Fantappie, Carmelo Irene, Luca Frattini, Samine J. Isaac, Enrico Konig, Francesca Zerbini, Simona Tavarini, Chiara Sammicheli, Fabiola Giusti, Ilaria Ferlenghi, Matteo Parri, Guido Grandi

FRONTIERS IN ONCOLOGY (2017)

Article Infectious Diseases

Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women

Monica Fabbrini, Fabio Rigat, Giovanna Tuscano, Emiliano Chiarot, Gilbert Donders, Roland Devlieger, Sara Filippini, Elisabetta Frigimelica, Pietro Forte, Frederick Wittke, Scott A. Halperin, Karen Slobod, Guido Grandi, Immaculada Margarit

JOURNAL OF INFECTION (2018)

Article Multidisciplinary Sciences

Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models

Emiliano Chiarot, Angela Spagnuolo, Silvia Maccari, Eleonora Naimo, Alessandra Acquaviva, Raffaella Cecchi, Bruno Galletti, Monica Fabbrini, Elena Mori, Paolo Ruggiero, Guido Grandi, Maria Rita Fontana, Giuliano Bensi, Immaculada Margarit

SCIENTIFIC REPORTS (2018)

Article Multidisciplinary Sciences

Identification of lipid A deacylase as a novel, highly conserved and protective antigen against enterohemorrhagic Escherichia coli

Maricarmen Rojas-Lopez, Manuele Martinelli, Valentina Brandi, Gregory Jubelin, Fabio Polticelli, Marco Soriani, Mariagrazia Pizza, Mickael Desvaux, Roberto Rosini

SCIENTIFIC REPORTS (2019)

Article Biotechnology & Applied Microbiology

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

Stefania Capone, Angelo Raggioli, Michela Gentile, Simone Battella, Armin Lahm, Andrea Sommella, Alessandra Maria Contino, Richard A. Urbanowicz, Romina Scala, Federica Barra, Adriano Leuzzi, Eleonora Lilli, Giuseppina Miselli, Alessia Noto, Maria Ferraiuolo, Francesco Talotta, Theocharis Tsoleridis, Concetta Castilletti, Giulia Matusali, Francesca Colavita, Daniele Lapa, Silvia Meschi, Maria Capobianchi, Marco Soriani, Antonella Folgori, Jonathan K. Ball, Stefano Colloca, Alessandra Vitelli

Summary: The study introduced a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike protein of SARS-CoV-2, which showed high immunogenicity in mice and macaques. The research highlighted the superiority of the pre-fusion stabilized Spike antigen in inducing ACE2-interfering, SARS-CoV-2-neutralizing antibodies. Selection of the vector backbone and preliminary data identified GRAd-COV2 as a potential COVID-19 vaccine candidate, supporting its translation into a phase I clinical trial.

MOLECULAR THERAPY (2021)

Article Cell Biology

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Simone Lanini, Stefania Capone, Andrea Antinori, Stefano Milleri, Emanuele Nicastri, Roberto Camerini, Chiara Agrati, Concetta Castilletti, Federica Mori, Alessandra Sacchi, Giulia Matusali, Roberta Gagliardini, Virginia Ammendola, Eleonora Cimini, Fabiana Grazioli, Laura Scorzolini, Federico Napolitano, Maria M. Plazzi, Marco Soriani, Aldo De Luca, Simone Battella, Andrea Sommella, Alessandra M. Contino, Federica Barra, Michela Gentile, Angelo Raggioli, Yufang Shi, Enrico Girardi, Markus Maeurer, Maria R. Capobianchi, Francesco Vaia, Mauro Piacentini, Guido Kroemer, Alessandra Vitelli, Stefano Colloca, Antonella Folgori, Giuseppe Ippolito

Summary: Safe and effective COVID-19 vaccines are crucial for ending the pandemic. A vaccine called GRAd-COV2, based on a gorilla adenovirus and expressing the spike protein of SARS-CoV-2, has been evaluated for safety and immunogenicity in healthy younger and older adults.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Oncology

Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells

Michele Tomasi, Elena Caproni, Mattia Benedet, Ilaria Zanella, Sebastiano Giorgetta, Mattia Dalsass, Enrico Koenig, Assunta Gagliardi, Laura Fantappie, Alvise Berti, Silvia Tamburini, Lorenzo Croia, Gabriele Di Lascio, Erika Bellini, Silvia Valensin, Giada Licata, Guido Sebastiani, Francesco Dotta, Federica Armanini, Fabio Cumbo, Francesco Asnicar, Aitor Blanco-Miguez, Eliana Ruggiero, Nicola Segata, Guido Grandi, Alberto Grandi

Summary: A growing body of evidence supports the important role of the gut microbiome in cancer immunity, and it has been found that microbiome proteins can induce specific T cells, which can inhibit tumor growth. Furthermore, personalized mucosal cancer vaccines can be developed using engineered microbes and Outer Membrane Vesicles.

FRONTIERS IN ONCOLOGY (2022)

Article Immunology

Bacterial Outer Membrane Vesicles as a Platform for the Development of a Broadly Protective Human Papillomavirus Vaccine Based on the Minor Capsid Protein L2

Silvia Tamburini, Yueru Zhang, Assunta Gagliardi, Gabriele Di Lascio, Elena Caproni, Mattia Benedet, Michele Tomasi, Riccardo Corbellari, Ilaria Zanella, Lorenzo Croia, Guido Grandi, Martin Mueller, Alberto Grandi

Summary: This study demonstrates that L2 epitopes can be efficiently expressed on the surface of E. coli outer membrane vesicles (OMVs), and a polypeptide composed of L2 epitopes from multiple serotypes shows broad cross-protective activity against HPV. This provides a highly effective and inexpensive solution for producing universal anti-HPV vaccines.

VACCINES (2023)

Article Immunology

Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine

Alberto Grandi, Michele Tomasi, Irfan Ullah, Cinzia Bertelli, Teresa Vanzo, Silvia Accordini, Assunta Gagliardi, Ilaria Zanella, Mattia Benedet, Riccardo Corbellari, Gabriele Di Lascio, Silvia Tamburini, Elena Caproni, Lorenzo Croia, Micol Rava, Valeria Fumagalli, Pietro Di Lucia, Davide Marotta, Eleonora Sala, Matteo Iannacone, Priti Kumar, Walther Mothes, Pradeep D. Uchil, Peter Cherepanov, Martino Bolognesi, Massimo Pizzato, Guido Grandi

Summary: The study demonstrates that engineered OMVs vaccines can induce effective immune responses, producing neutralizing antibodies and protecting animals from SARS-CoV-2 infection. Furthermore, the vaccine can also elicit immune responses against the Omicron BA.1 and BA.5 variants. OMV-based SARS-CoV-2 vaccines, with the convenience of engineering, production, and distribution, can be a crucial addition to the currently available vaccines.

VACCINES (2023)

Meeting Abstract Biotechnology & Applied Microbiology

Evaluation of Human Cardiomyocytes for Use in a Potency Assay for XC001, an Adenoviral Gene Therapy Vector for Treatment of Refractory Angina

Alexander Gaidamaka, Barb Thorne, Francesco Talotta, Albert Gianchetti, Remi Gloeckler, Marco Soriani

MOLECULAR THERAPY (2021)

No Data Available